natgillin/translations-raw huggingface dataset:
Maksimalt målniveau for VWF:RCo i plasma
VWF:RCo Target Peak Plasma Level
0,50 IE/ml
0.50 IU/mL
VEYVONDI 1300 IE pulver og solvens til injektionsvæske, opløsning Hver pakning indeholder: - pulver i et hætteglas (type I-glas) med prop af butylgummi - 10 ml solvens i et hætteglas (type I-glas) med gummiprop (bromobutyl) - et rekonstitutionssæt (Mix2Vial)
VEYVONDI 1300 IU powder and solvent for solution for injection Each pack contains: - powder in a vial (type I glass), with a butyl rubber stopper
Hvis FVIII:C-niveauet er på det anbefalede målniveau på: - mindst 0,4 IE/ml ved mindre og orale kirurgiske indgreb og - mindst 0,8 IE/ml ved større indgreb, skal en dosis VEYVONDI administreres alene inden for 1 time før indgrebet.
To ensure pre-operative endogenous FVIII levels of at least 0.4 IU/mL for minor and oral and 0.8 IU/mL for major surgery, a dose of 40-60 IU/kg VEYVONDI may be administered 12-24 hours (pre-operative dose) prior to initiating elective surgery.
Intet billede
Image example
Instruktioner vedrørende indgivelse
Instructions for Administration
Fase 3 PK80 VEYVONDI (studiet 071001)
VEYVONDI (Study 071001)
Opløsningen skal langsomt indgives intravenøst (se pkt.
The solution should be slowly administered intravenously (see section 4.2) not exceeding 4 mL/min.
Hedeture
Haemorrhage
Cl b
AUC0-inf d
Hvert år gennemgår Det Europæiske Lægemiddelagentur (EMA) alle nye oplysninger, der måtte foreligge, og ajourfører om nødvendigt dette sammendrag.
Every year, the European Medicines Agency (EMA) will review any new information that may become available and this summary will be updated as necessary.
Vaccinen gives i overensstemmelse med de officielle anbefalinger.
The vaccine would be given according to official recommendations.
Hvis der er udbrudt en pandemi, kan det dog være hensigtsmæssigt at vaccinere sådanne patienter, forudsat at der er genoplivningsudstyr til rådighed.
If a pandemic has started, however, it may be appropriate to give the vaccine to these patients, as long as facilities for resuscitation are available.
Den første hovedundersøgelse omfattede 561 raske frivillige, hvoraf de 281 var over 60 år.
One main study in adults included 561 healthy volunteers, 281 of whom were over the age of 60 years.
De kan dernæst afprøve denne vaccine på mennesker for at se, hvordan de reagerer på den, hvorved de kan forudsige, hvordan mennesker vil reagere, når influenzastammen, der er årsag til pandemien, indgår i vaccinen.
They can then test this vaccine to see how people react to it, allowing them to predict how people will react when the flu strain causing the pandemic is included.
Ifølge de kriterier, der er fastlagt af Udvalget for Humanmedicinske Lægemidler (CHMP), skal en mockup-vaccine frembringe en beskyttende mængde antistoffer hos mindst 70 % af voksne for at kunne anses for egnet.
According to criteria laid down by the Committee for Medicinal Products for Human Use (CHMP), a mock-up vaccine needs to bring about protective levels of antibodies in at least 70% of adults for it to be considered suitable.
Undersøgelsen så også på virkningen af en boosterdosis efter 12 måneder hos nogle af børnene.
The study also looked at the effect of a booster dose given after twelve months in some of the children.
Vaccinen indeholder influenzastammen A/VietNam/1203/2004 (H5N1).
The vaccine contains a flu strain called A/VietNam/1203/2004 (H5N1).
Vaccinen må ikke gives til personer, der har haft en anafylaktisk reaktion (svær allergisk reaktion) over for en af vaccinens komponenter eller over for et af de sporstoffer, den indeholder (meget lavt), f.eks. formaldehyd, benzonase eller sukrose.
The vaccine must not be given to people who have had an anaphylactic reaction (severe allergic reaction) to any of the components of the vaccine, or to any of the substances found at trace (very low) levels in the vaccine, such as formaldehyde, benzonase or sucrose.
Den indeholder influenzavira, som er blevet inaktiveret (dræbt).
It contains influenza (flu) viruses that have been inactivated (killed).
Det primære effektmål var produktionen af beskyttende niveauer af antistoffer 21 dage efter den anden vaccination.
The main measure of effectiveness was the production of protective levels of antibodies 21 days after the second vaccination.
En influenzapandemi forekommer, når der opstår en ny type (stamme) af en influenzavirus, der let smitter fra menneske til menneske, fordi mennesker ikke har nogen immunitet over for den. En pandemi kan berøre de fleste lande og regioner i verden.
A flu pandemic happens when a new type (strain) of flu virus appears that can spread easily from person to person because people have no immunity (protection) against it. A pandemic can affect most countries and regions around the world.
I stedet kan virksomhederne fremstille en vaccine med en influenzavirusstamme, der specifikt udvælges, fordi ingen har været udsat for den, og ingen er immune over for den.
Instead, they can prepare a vaccine that contains a strain of flu virus specifically chosen because nobody has been exposed to it, and to which nobody is immune.
Denne vaccine er den samme som Celvapan H5N1-mockup-vaccinen, der tidligere er godkendt i Den Europæiske Union (EU).
This vaccine is the same as the Celvapan H5N1 mock-up vaccine, which was previously authorised in the European Union (EU).
Vaccinen indeholder en virus kaldet H5N1, som er blevet inaktiveret (dræbt), så den ikke længere forårsager sygdom.
This vaccine contains a virus called H5N1 that has been inactivated (killed) so that it does not cause any disease.
Det er en vaccine, der kun må bruges, når Verdenssundhedsorganisationen eller Den Europæiske Union (EU) officielt har erklæret, at der er udbrudt en pandemi.
It should only be used once a flu pandemic has been officially declared by the World Health Organization or European Union (EU).
Den fuldstændige EPAR for Pandemic Influenza Vaccine H5N1 Baxter AG findes på agenturets websted under: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
The full EPAR for Pandemic Influenza Vaccine H5N1 Baxter AG can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
influenzavaccine, hele virion, dyrket i vero-celler (kontinuerlig cellelinje fra pattedyr), inaktiveret, indeholder antigen af pandemisk stamme
whole virion influenza virus, propagated in vero cells (continuous cell line of mammalian origin), inactivated, containing antigen of pandemic strain
21 dage efter den anden injektion havde 72 % af de voksne under 60 år (192 ud af 265) og 74 % af dem over 60 år (200 ud af 270) dannet nok antistoffer til at være beskyttet mod H5N1.
At 21 days after the second injection, 72% of the adults below 60 years of age (192 out of 265) and 74% of those above 60 years of age (200 out of 270) had levels of antibodies that would protect them against H5N1.
Europa-Kommissionen udstedte en markedsføringstilladelse med gyldighed i hele Den Europæiske Union for Pandemic Influenza Vaccine H5N1 Baxter AG den 16. oktober 2009.
The European Commission granted a marketing authorisation valid throughout the European Union for Pandemic Influenza Vaccine H5N1 Baxter AG on 16 October 2009.
En mockup-vaccine er en særlig vaccinetype, der er udviklet for at kontrollere en fremtidig pandemi.
This is a special type of vaccine that is designed to help with the management of a future pandemic.
Det forklarer, hvordan Udvalget for Humanmedicinske Lægemidler (CHMP) vurderede lægemidlet og nåede frem til sin udtalelse til fordel for udstedelse af en markedsføringstilladelse og til sine anbefalinger om anvendelsesbetingelserne for Pandemic Influenza Vaccine H5N1 Baxter AG.
It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Pandemic Influenza Vaccine H5N1 Baxter AG.
Mængden af antistoffer faldt langsomt over det efterfølgende år, men en boosterdosis efter 12 måneder gjorde, at mellem 93 % og 100 % af de børn, som fik den, dannede nok antistoffer til at være beskyttet.
Although levels of antibodies slowly fell over the year after vaccination, a booster dose after 12 months resulted in protective levels of antibodies in 93 to 100% of children who received it.
Når virksomheden, som fremstiller Pandemic Influenza Vaccine H5N1 Baxter AG, inkluderer den influenzastamme, som er ansvarlig for pandemien, i vaccinen, skal den indsamle oplysninger om sikkerhed og virkning af den endelige pandemivaccine og forelægge disse for CHMP til evaluering.
When the company that makes Pandemic Influenza Vaccine H5N1 Baxter AG includes the flu strain responsible for a pandemic in the vaccine, it will collect information on the safety and effectiveness of the final pandemic vaccine, and submit this to the CHMP for evaluation.
Hvis du ønsker yderligere oplysninger om behandling med Pandemic Influenza Vaccine H5N1 Baxter AG, kan du læse indlægssedlen (også en del af denne EPAR) eller kontakte din læge eller dit apotek.
For more information about treatment with Pandemic Influenza Vaccine H5N1 Baxter AG, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Virksomheden, som fremstiller Celvapan H5N1-mockup-vaccinen, har indvilget i, at dets videnskabelige data kan anvendes på Pandemic Influenza Vaccine H5N1 Baxter AG (”informeret samtykke”).
The company that made the Celvapan H5N1 mock-up vaccine has agreed that its scientific data can be used for Pandemic Influenza Vaccine H5N1 Baxter AG (‘informed consent').
Hos børnene, efter den anden 7,5-mikrogram dosis, havde 85 % af børnene i alderen 9-17 år, 73 % af børnene i alderen 3-8 år og 69 % af børnene på mellem 6 og 35 måneder ligeledes dannet nok antistoffer til at være beskyttet 21 dage efter den anden injektion.
Similarly in children, after the second 7.5-microgram dose, 85% of children aged 9 to 17 years, 73% of those 3 to 8 years, and 69% of those aged 6 to 35 months had protective levels of antibodies 21 days after the second injection.
Når en person vaccineres, opfatter immunsystemet det inaktiverede virus som ”fremmed” og danner antistoffer mod det. Immunsystemet kan således danne antistoffer hurtigere, når det eksponeres for samme virus igen.
When a person is given the vaccine, the immune system recognises the inactivated virus as ‘foreign' and makes antibodies against it.
Pandemic Influenza Vaccine H5N1 Baxter AG gives ved injektion i skuldermusklen eller låret i to doser med mindst tre ugers mellemrum.
Pandemic Influenza Vaccine H5N1 Baxter AG is given by injection into the shoulder muscle or thigh in two doses, at least three weeks apart.
Dette er et sammendrag af den europæiske offentlige vurderingsrapport (EPAR) for Pandemic Influenza Vaccine H5N1 Baxter AG.
This is a summary of the European public assessment report (EPAR) for Pandemic Influenza Vaccine H5N1 Baxter AG.
De hyppigste bivirkninger ved Pandemic Influenza Vaccine H5N1 Baxter AG (som optræder hos flere end 1 ud af 10 patienter) hos voksne er hovedpine, træthed og smerter på injektionsstedet.
The most common side effects with Pandemic Influenza Vaccine H5N1 Baxter AG in adults (seen in more than 1 person in 10) are headache, fatigue (tiredness) and pain at the site of the injection.
På baggrund af denne er der anført sikkerhedsoplysninger i produktresuméet og indlægssedlen for Pandemic Influenza Vaccine H5N1 Baxter AG, herunder passende forholdsregler, som patienter og sundhedspersonale bør følge.
Based on this plan, safety information has been included in the summary of product characteristics and the package leaflet for Pandemic Influenza Vaccine H5N1 Baxter AG, including the appropriate precautions to be followed by healthcare professionals and patients.
Der er udarbejdet en risikostyringsplan for at sikre, at Pandemic Influenza Vaccine H5N1 Baxter AG anvendes så sikkert som muligt.
A risk management plan has been developed to ensure that Pandemic Influenza Vaccine H5N1 Baxter AG is used as safely as possible.
Det betyder, at det ikke har været muligt at opnå fyldestgørende oplysninger om den endelige pandemiske vaccine, da det er en mockup-vaccine, som endnu ikke indeholder den influenzavirusstamme, der forårsager en pandemi.
This means that, because the vaccine is a mock up and does not yet contain the strain of flu virus that is causing a pandemic, it has not been possible to obtain full information about the final pandemic vaccine.
Virkningen blev hovedsagelig bedømt på mængden af antistoffer i forhold til mængden af influenzavirus i blodet inden vaccinationen, på datoen for anden vaccination (dag 21), og 21 dage efter anden vaccination (dag 42).
The study looked at the ability of two 7.5 microgram doses of the vaccine, given 21 days apart, to trigger the production of antibodies (‘immunogenicity').The main measures of effectiveness were the levels of antibodies against the flu virus in the blood before vaccination, on the day of the second injection (day 21), and 21 days after the second vaccination (day 42).
Den anden hovedundersøgelse omfattede 305 børn i alderen 9-17 år, 306 børn i alderen 3-8 år og 73 børn på mellem 6 og 35 måneder.
The second main study involved 305 children aged 9 to 17 years, 306 aged 3 to 8 years and 73 aged 6 to 35 months, and also examined the effect of two 7.5 microgram doses of the vaccine 21 days apart.
Pandemic Influenza Vaccine H5N1 Baxter AG er blevet godkendt under ‘særlige omstændigheder'.
Pandemic Influenza Vaccine H5N1 Baxter AG has been authorised under ‘Exceptional Circumstances'.
Undersøgelsen viste, at Pandemic Influenza Vaccine H5N1 Baxter AG udløste en antistofrespons, der opfyldte disse kriterier.
The study showed that Pandemic Influenza Vaccine H5N1 Baxter AG produced an antibody response that met these criteria.
CHMP konkluderede, at fordelene ved Pandemic Influenza Vaccine H5N1 Baxter AG var større end risiciene i alle de undersøgte grupper, og anbefalede udstedelse af en markedsføringstilladelse for Pandemic Influenza Vaccine H5N1 Baxter AG.
The CHMP decided that Pandemic Influenza Vaccine H5N1 Baxter AG's benefits are greater than its risks in all age groups investigated and recommended that it be given marketing authorisation.
De vira, der anvendes i Pandemic Influenza Vaccine H5N1 Baxter AG, dyrkes i pattedyrceller (‘veroceller') i modsætning til andre influenzavacciner, der dyrkes i hønseæg.
The viruses used in Pandemic Influenza Vaccine H5N1 Baxter AG are grown in mammal cells (‘vero cells'), unlike those in some other flu vaccines, which are grown in hen's eggs.
Pandemic Influenza Vaccine H5N1 Baxter AG er en vaccine, der gives ved injektion.
Pandemic Influenza Vaccine H5N1 Baxter AG is a vaccine that is given by injection.
Pandemic Influenza Vaccine H5N1 Baxter AG er en vaccine til forebyggelse af ‘pandemisk' influenza.
Pandemic Influenza Vaccine H5N1 Baxter AG is a vaccine to prevent ‘pandemic' flu.
Den fuldstændige liste over de indberettede bivirkninger ved Pandemic Influenza Vaccine H5N1 Baxter AG fremgår af indlægssedlen.
For the full list of all side effects reported with Pandemic Influenza Vaccine H5N1 Baxter AG, see the package leaflet.
Hvilke foranstaltninger træffes der for at sikre risikofri og effektiv anvendelse af Pandemic Influenza Vaccine H5N1 Baxter AG?
What measures are being taken to ensure the safe and effective use of Pandemic Influenza Vaccine H5N1 Baxter AG?
Andre oplysninger om Pandemic Influenza Vaccine H5N1 Baxter AG
Other information about Pandemic Influenza Vaccine H5N1 Baxter AG
Hvilke oplysninger afventes der stadig for Pandemic Influenza Vaccine H5N1 Baxter AG?
What information is still awaited for Pandemic Influenza Vaccine H5N1 Baxter AG?
Under en pandemi skal virusstammen i Pandemic Influenza Vaccine H5N1 Baxter AG erstattes med den stamme, der forårsager pandemien, inden vaccinen kan bruges.
Baxter AG will have to be replaced by the strain causing the pandemic before the vaccine can be used.
Hvorfor blev Pandemic Influenza Vaccine H5N1 Baxter AG godkendt?
Why has Pandemic Influenza Vaccine H5N1 Baxter AG been approved?
Hvilken risiko er der forbundet med Pandemic Influenza Vaccine H5N1 Baxter AG?
What is the risk associated with Pandemic Influenza Vaccine H5N1 Baxter AG?
Pandemic Influenza Vaccine H5N1 Baxter AG er en ‘mockup'-vaccine.
Pandemic Influenza Vaccine H5N1 Baxter AG is a ‘mock-up' vaccine.
Hvordan blev Pandemic Influenza Vaccine H5N1 Baxter AG undersøgt?
How has Pandemic Influenza Vaccine H5N1 Baxter AG been studied?
Hvad er Pandemic Influenza Vaccine H5N1 Baxter AG?
What is Pandemic Influenza Vaccine H5N1 Baxter AG?
Hvad anvendes Pandemic Influenza Vaccine H5N1 Baxter AG til?
What is Pandemic Influenza Vaccine H5N1 Baxter AG used for?
Hvordan anvendes Pandemic Influenza Vaccine H5N1 Baxter AG?
How is Pandemic Influenza Vaccine H5N1 Baxter AG used?
Først når pandemien er brudt ud, ved man, hvilken influenzavirusstamme der forårsager den.
Before a pandemic starts, nobody knows which strain of flu virus will be involved, so pharmaceutical companies cannot prepare the correct vaccine in advance.
Hvordan virker Pandemic Influenza Vaccine H5N1 Baxter AG?
How does Pandemic Influenza Vaccine H5N1 Baxter AG work?
Metabolismen hos hest er ikke undersøgt.
The metabolism in horses has not been investigated.
Dato for ændring af teksten
DATE OF REVISION OF THE TEXT
Behandling af kalve med Emdocam 20 minutter før afhorning reducerer postoperativ smerte.
Treatment of calves with Emdocam 20 minutes before dehorning reduces post-operative pain.
Dato for første markedsføringstilladelse: 18.08.2011 Dato for seneste fornyelse af markedsføringstilladelse: 21.06.2016
Date of first authorisation: 18.08.2011 Date of last renewal: 21.06.2016
Emdocam alene vil ikke give tilstrækkelig smertelindring under afhorning.
Emdocam alone will not provide adequate pain relief during the dehorning procedure.
Personer med kendt overfølsomhed over for nonsteroide antiinflammatoriske lægemidler (NSAID-præparater) bør undgå kontakt med veterinærlægemidlet.
People with known hypersensitivity to Non-Steroidal AntiInflammatory Drugs (NSAIDs) should avoid contact with the veterinary medicinal product.
Det reducerer leukocytinfiltrationen i det betændte væv.
It reduces leukocyte infiltration into the inflamed tissue.
FREMSTILLERENS BATCHNUMMER
MANUFACTURER´S BATCH NUMBER
I meget sjældne tilfælde kan anafylaktiske reaktioner som kan være alvorlige (herunder dødelige) forekomme.
In very rare cases anaphylactoid reactions, which may be serious (including fatal), may occur and should be treated symptomatically.
Bryd ikke hætteglasset mere end 50 gange.
Do not breach the vial more than 50 times.
Om nødvendigt kan en yderligere dosis gives efter 24 timer.
If required, a second administration of meloxicam can be given after 24 hours.
Hjælpestofferne nævnt i afsnit 6.1 i produktresuméet er enten tilladte stoffer hvor ingen MRL-værdier er påkrævet, hvilket er indikeret i tabel 1 i bilaget til Kommissionens forordning (EU) nr. 37/2010 eller som benyttet i produktet ikke anses for at være omfattet af forordning (EF) nr. 470/2009.
The excipients listed in section 6.1 of the SPC are either allowed substances for which table 1 of annex to Commission Regulation (EU) No 37/2010 indicates that no MRLs are required or are considered as not falling within the scope of Regulation (EC) No 470/2009 when used as in this product.
Indehaver af markedsføringstilladelsen Emdoka bvba
Marketing authorisation holder Emdoka bvba
Bryd ikke hætteglasset mere end 50 gange
Do not broach the vial more than 50 times.
Etanol (96 %) 150 mg Klar gul injektionsvæske, opløsning.
Ethanol (96%) 150 mg Clear yellow solution for injection.
15 µg/kg Mælk
15 μg/kg Milk
De højeste meloxicamkoncentrationer ses i lever og nyrer.
The highest meloxicam concentrations are to be found in liver and kidney.
Meloxicam i Emdocam 20 mg/ml injektionsvæske, opløsning til kvæg, gris og heste er et tilladt stof beskrevet i tabel 1 i bilaget til Kommissionens forordning (EU) nr. 37/2010:
Meloxicam in Emdocam 20 mg/ml solution for injection for cattle, pigs and horses is an allowed substance as described in table 1 of the annex to Commission Regulation (EU) No 37/2010:
EXP {MM/ÅÅÅÅ}
EXP {month/year}
Mælk: 5 dage
Milk: 5 days
Navn og adresse på fremstilleren ansvarlig for batchfrigivelse Produlab Pharma bv
Name and address of the manufacturer responsible for batch release Produlab Pharma bv
Hvert hætteglas er lukket med en bromobutylgummiprop og forseglet med en aluminiumshætte.
Each vial is closed with a bromobutyl rubber stopper and sealed with an aluminium cap.
Hos heste kan forekomme en forbigående hævelse på injektionsstedet, som forsvinder uden indgriben.
In horses, a transient swelling at the injection site can occur but resolves without intervention.
Opbevaringstid for veterinærlægemidlet i salgspakning: 3 år Opbevaringstid efter første åbning af den indre emballage: 28 dage
Shelf-life of the veterinary medicinal product as packaged for sale: 3 years Shelf-life after first opening the immediate packaging: 28 days
Emdoka bvba J. Lijsenstraat 16 B-2321 Hoogstraten Belgien
Emdoka bvba J. Lijsenstraat 16 B-2321 Hoogstraten Belgium
Meloxicam elimineres med halveringstider på 26 og 17,5 time efter subkutan injektion hos henholdsvis ungkvæg og lakterende køer.
Meloxicam is eliminated with a half-life of 26 hours and 17.5 hours after subcutaneous injection in young cattle and lactating cows, respectively.
Lægemidler må ikke bortskaffes sammen med spildevand eller husholdningsaffald.
Any unused medicines should not be disposed of via wastewater or household waste.
Hvis der forekommer bivirkninger, bør behandlingen afbrydes, og dyrlægen kontaktes.
If adverse reactions occur, treatment should be discontinued and the advice of a veterinarian should be sought.
Til anvendelse ved akut respiratorisk infektion i kombination med passende antibiotikabehandling med henblik på at reducere kliniske symptomer hos kvæg.
For use in acute respiratory infection with appropriate antibiotic therapy to reduce clinical signs in cattle.
Brug ikke dette veterinærlægemiddel efter den udløbsdato, der står på den ydre emballage og hætteglasset efter EXP. Udløbsdatoen refererer til den sidste dag i den pågældende måned.
Do not use this veterinary medicinal product after the expiry date which is stated on the carton and vial after EXP.
TEKSTEN ”TIL DYR”
THE WORDS "FOR ANIMAL TREATMENT ONLY"
Til supplerende behandling af puerperal sepsis og toksikæmi (mastitis-metritis-agalaktisk syndrom) med passende antibiotikabehandling.
For adjunctive therapy in the treatment of puerperal septicaemia and toxaemia (mastitis-metritis-agalactia syndrome) with appropriate antibiotic therapy.
Da der ikke foreligger undersøgelser vedrørende eventuelle uforligeligheder, må dette lægemiddel ikke blandes med andre lægemidler.
In the absence of compatibility studies, this veterinary medicinal product must not be mixed with other veterinary medicinal products.
EXP.{MM/ÅÅÅÅ} Efter åbning anvendes inden…
EXP {month/year} Once broached, use by…
Heste: i.v.
Horses: I.V.
Hyppigheden af bivirkninger er defineret som: - Meget almindelig (flere end 1 ud af 10 behandlede dyr, der viser bivirkninger i løbet af en behandling) - Almindelige (flere end 1, men færre end 10 dyr af 100 behandlede dyr) - Ikke almindelige (flere end 1, men færre end 10 dyr af 1.000 behandlede dyr) - Sjældne (flere end 1, men færre end 10 dyr ud af 10.000 behandlede dyr) -.
The frequency of adverse reactions is defined using the following convention: - very common (more than 1 in 10 animals treated displaying adverse reactions) - common (more than 1 but less than 10 animals in 100 animals treated) - uncommon (more than 1 but less than 10 animals in 1,000 animals treated) - rare (more than 1 but less than 10 animals in 10,000 animals treated) - very rare (less than 1 animal in 10,000 animals, including isolated reports treated).
Til supplerende behandling af akut mastitis i kombination med antibiotikabehandling.
For adjunctive therapy in the treatment of acute mastitis, in combination with antibiotic therapy.
Pakningsstørrelse med 1 farveløst Type I hætteglas hver indeholdende 50 ml, 100 ml eller 250 ml.
Pack size of 1 colourless Type I glass vial containing 50 ml, 100 ml or 250 ml.